Viatris Inc. Common Stock (VTRS) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that...
Viatris Inc. Common Stock (VTRS) currently trades at a P/E ratio of 255.39 (historical range: 5.78–268.21, median: 15.51), placing it at the 91th percentile — expensive relative to its history, P/S ratio of 1.45 (range: 0.47–1.45, 100th percentile — expensive relative to its history), EV/EBITDA of 21.30 (range: 15.95–2462.20, 33th percentile).
Over the historical period (2021-09-14 to 2026-10-16), Viatris Inc. Common Stock's P/E ratio has expanded by 1135% over the observed period (from an average of 20.2 to 249.7).
Viatris Inc. Common Stock trades above its historical valuation range, with most metrics above their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 255.39 | 15.51 | 91th | expensive relative to its history |
| P/S Ratio | 1.45 | 0.81 | 100th | expensive relative to its history |
| EV/EBITDA | 21.30 | 27.51 | 33th | below its historical average |
| FCF Yield | 9.12% | 17.80% | 1th | expensive relative to its history |
Viatris Inc. Common Stock (VTRS) Valuation & P/E History
Viatris Inc. Common Stock (VTRS) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry currently trading at $18.59 with a market capitalization of $21.4 billion. This page provides historical valuation analysis for VTRS based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 255.39 is above the historical median of 15.51, placing VTRS at the 91th percentile of its valuation range. The P/S ratio of 1.45 compares to a median of 0.81.
VTRS Valuation Metrics & Historical Range
The valuation table above shows Viatris Inc. Common Stock's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether VTRS is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests VTRS is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Viatris Inc. Common Stock.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is VTRS Overvalued or Undervalued?
Viatris Inc. Common Stock trades above its historical valuation range, with most metrics above their median levels. The overall valuation percentile of 75 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive VTRS is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full VTRS analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.VTRS trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.